Towards Improving the Efficacy of PSMA-Targeting Radionuclide Therapy for Late-Stage Prostate Cancer—Combination Strategies

PURPOSE OF REVIEW: [(177)Lu]Lu-PSMA-617 is a radiopharmaceutical that emits beta-minus radiation and targets prostate-specific membrane antigen (PSMA)-positive prostate cancer. Despite its clinical success, there are still patients not showing sufficient response rates. This review compiles latest s...

Descripción completa

Detalles Bibliográficos
Autores principales: Arbuznikova, Daria, Eder, Matthias, Grosu, Anca-Ligia, Meyer, Philipp T., Gratzke, Christian, Zamboglou, Constantinos, Eder, Ann-Christin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10640479/
https://www.ncbi.nlm.nih.gov/pubmed/37861915
http://dx.doi.org/10.1007/s11912-023-01458-6
_version_ 1785146640727801856
author Arbuznikova, Daria
Eder, Matthias
Grosu, Anca-Ligia
Meyer, Philipp T.
Gratzke, Christian
Zamboglou, Constantinos
Eder, Ann-Christin
author_facet Arbuznikova, Daria
Eder, Matthias
Grosu, Anca-Ligia
Meyer, Philipp T.
Gratzke, Christian
Zamboglou, Constantinos
Eder, Ann-Christin
author_sort Arbuznikova, Daria
collection PubMed
description PURPOSE OF REVIEW: [(177)Lu]Lu-PSMA-617 is a radiopharmaceutical that emits beta-minus radiation and targets prostate-specific membrane antigen (PSMA)-positive prostate cancer. Despite its clinical success, there are still patients not showing sufficient response rates. This review compiles latest studies aiming at therapy improvement in [(177)Lu]Lu-PSMA-617-naïve and -resistant patients by alternative or combination treatments. RECENT FINDINGS: A variety of agents to combine with [(177)Lu]Lu-PSMA-617 are currently under investigation including alpha radiation-emitting pharmaceuticals, radiosensitizers, taxane chemotherapeutics, androgen receptor pathway inhibitors, immune checkpoint inhibitors, and external beam radiation. Actinium-225 ((225)Ac)-labeled PSMA-targeting inhibitors are the most studied pharmaceuticals for combination therapy or as an alternative for treatment after progression under [(177)Lu]Lu-PSMA-617 therapy. SUMMARY: Alpha emitters seem to have a potential of achieving a response to PSMA-targeting radionuclide therapy in both initial non-responders or responders to [(177)Lu]Lu-PSMA-617 later developing treatment resistance. Emerging evidence for immunostimulatory effects of radiopharmaceuticals and first prospective studies support the combination of [(177)Lu]Lu-PSMA-617 and immune checkpoint inhibition for late-stage prostate cancer.
format Online
Article
Text
id pubmed-10640479
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-106404792023-11-14 Towards Improving the Efficacy of PSMA-Targeting Radionuclide Therapy for Late-Stage Prostate Cancer—Combination Strategies Arbuznikova, Daria Eder, Matthias Grosu, Anca-Ligia Meyer, Philipp T. Gratzke, Christian Zamboglou, Constantinos Eder, Ann-Christin Curr Oncol Rep Article PURPOSE OF REVIEW: [(177)Lu]Lu-PSMA-617 is a radiopharmaceutical that emits beta-minus radiation and targets prostate-specific membrane antigen (PSMA)-positive prostate cancer. Despite its clinical success, there are still patients not showing sufficient response rates. This review compiles latest studies aiming at therapy improvement in [(177)Lu]Lu-PSMA-617-naïve and -resistant patients by alternative or combination treatments. RECENT FINDINGS: A variety of agents to combine with [(177)Lu]Lu-PSMA-617 are currently under investigation including alpha radiation-emitting pharmaceuticals, radiosensitizers, taxane chemotherapeutics, androgen receptor pathway inhibitors, immune checkpoint inhibitors, and external beam radiation. Actinium-225 ((225)Ac)-labeled PSMA-targeting inhibitors are the most studied pharmaceuticals for combination therapy or as an alternative for treatment after progression under [(177)Lu]Lu-PSMA-617 therapy. SUMMARY: Alpha emitters seem to have a potential of achieving a response to PSMA-targeting radionuclide therapy in both initial non-responders or responders to [(177)Lu]Lu-PSMA-617 later developing treatment resistance. Emerging evidence for immunostimulatory effects of radiopharmaceuticals and first prospective studies support the combination of [(177)Lu]Lu-PSMA-617 and immune checkpoint inhibition for late-stage prostate cancer. Springer US 2023-10-20 2023 /pmc/articles/PMC10640479/ /pubmed/37861915 http://dx.doi.org/10.1007/s11912-023-01458-6 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Arbuznikova, Daria
Eder, Matthias
Grosu, Anca-Ligia
Meyer, Philipp T.
Gratzke, Christian
Zamboglou, Constantinos
Eder, Ann-Christin
Towards Improving the Efficacy of PSMA-Targeting Radionuclide Therapy for Late-Stage Prostate Cancer—Combination Strategies
title Towards Improving the Efficacy of PSMA-Targeting Radionuclide Therapy for Late-Stage Prostate Cancer—Combination Strategies
title_full Towards Improving the Efficacy of PSMA-Targeting Radionuclide Therapy for Late-Stage Prostate Cancer—Combination Strategies
title_fullStr Towards Improving the Efficacy of PSMA-Targeting Radionuclide Therapy for Late-Stage Prostate Cancer—Combination Strategies
title_full_unstemmed Towards Improving the Efficacy of PSMA-Targeting Radionuclide Therapy for Late-Stage Prostate Cancer—Combination Strategies
title_short Towards Improving the Efficacy of PSMA-Targeting Radionuclide Therapy for Late-Stage Prostate Cancer—Combination Strategies
title_sort towards improving the efficacy of psma-targeting radionuclide therapy for late-stage prostate cancer—combination strategies
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10640479/
https://www.ncbi.nlm.nih.gov/pubmed/37861915
http://dx.doi.org/10.1007/s11912-023-01458-6
work_keys_str_mv AT arbuznikovadaria towardsimprovingtheefficacyofpsmatargetingradionuclidetherapyforlatestageprostatecancercombinationstrategies
AT edermatthias towardsimprovingtheefficacyofpsmatargetingradionuclidetherapyforlatestageprostatecancercombinationstrategies
AT grosuancaligia towardsimprovingtheefficacyofpsmatargetingradionuclidetherapyforlatestageprostatecancercombinationstrategies
AT meyerphilippt towardsimprovingtheefficacyofpsmatargetingradionuclidetherapyforlatestageprostatecancercombinationstrategies
AT gratzkechristian towardsimprovingtheefficacyofpsmatargetingradionuclidetherapyforlatestageprostatecancercombinationstrategies
AT zamboglouconstantinos towardsimprovingtheefficacyofpsmatargetingradionuclidetherapyforlatestageprostatecancercombinationstrategies
AT ederannchristin towardsimprovingtheefficacyofpsmatargetingradionuclidetherapyforlatestageprostatecancercombinationstrategies

Ejemplares similares